BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 22926855)

  • 1. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
    Mowry EM; Waubant E; McCulloch CE; Okuda DT; Evangelista AA; Lincoln RR; Gourraud PA; Brenneman D; Owen MC; Qualley P; Bucci M; Hauser SL; Pelletier D
    Ann Neurol; 2012 Aug; 72(2):234-40. PubMed ID: 22926855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
    Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index, but not vitamin D status, is associated with brain volume change in MS.
    Mowry EM; Azevedo CJ; McCulloch CE; Okuda DT; Lincoln RR; Waubant E; Hauser SL; Pelletier D
    Neurology; 2018 Dec; 91(24):e2256-e2264. PubMed ID: 30429274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
    van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
    Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
    Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
    Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
    Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis.
    Wybrecht D; Reuter F; Zaaraoui W; Faivre A; Crespy L; Rico A; Malikova I; Confort-Gouny S; Soulier E; Cozzone PJ; Pelletier J; Ranjeva JP; Audoin B
    Mult Scler; 2012 Nov; 18(11):1585-91. PubMed ID: 22454097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
    Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
    Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.